Back to Search Start Over

Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database

Authors :
Dennis Brinker
Kristin J. Meyers
Jonathan I. Silverberg
Evangeline Pierce
Robert Goodloe
Walter Deberdt
Maria Jose Rueda
Source :
Dermatology and Therapy
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

Introduction Atopic dermatitis (AD) is associated with risk factors for venous thromboembolism (VTE). However, the risk of VTE among this population is unknown. The aim of this study was to assess the risk of VTE among adults with AD and compare the risk vs. matched non-AD controls. Methods This retrospective study used claims data from the IBM Watson MarketScan® Commercial Claims and Encounters, Medicare Supplemental, and Medicaid databases to identify adults aged 18 years or older with AD. Incidence rates (IR) per 100 person-years (PY) of VTE were reported for three cohorts: overall AD, moderate-to-severe AD, and non-AD controls matched by age, sex, and calendar time to the overall cohort. Cox proportional hazards regression was used to estimate hazard ratios (HR) for VTE risk. Results Overall, 198,685 patients with AD were identified. Crude VTE IRs were 0.24 for AD overall, 0.31 for moderate-to-severe AD, and 0.25 for non-AD controls. VTE risk was similar in patients with AD vs. non-AD controls (partially adjusted HR 1.00, 95% confidence interval [CI] 0.92, 1.09). VTE risk was greater in patients with moderate-to-severe AD vs. non-AD controls in partially adjusted models (HR 1.24, 95% CI 1.13, 1.36), but not after adjustment for healthcare use and VTE risk factors (HR 0.95, 95% CI 0.85, 1.07). Conclusions AD was not an independent risk factor for VTE, and the risk of VTE among patients with AD was low. These findings provide valuable context for understanding VTE risk among patients with AD, which is particularly relevant as advanced therapies for the treatment of moderate to severe AD, such as janus kinase inhibitors, become available. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-021-00538-4.

Details

ISSN :
21909172 and 21938210
Volume :
11
Database :
OpenAIRE
Journal :
Dermatology and Therapy
Accession number :
edsair.doi.dedup.....6e28e541322ef48eed8cfacaa9fc8c7d
Full Text :
https://doi.org/10.1007/s13555-021-00538-4